Despite its strong efficacy, Remicade is facing increased competition from newer drugs and the prospect of pipeline drugs set to launch in the coming years.
Among branded ulcerative colitis treatments, 84% of US gastroenterologists expect Zeposia to see an increase in prescription volume over the next 12 months, according to new research on the ulcerative colitis marketplace published by Vivisum Partners.
